Liquidia Corp CFO Michael Kaseta sells shares worth $13,503

Published 04/03/2025, 22:34
Liquidia Corp CFO Michael Kaseta sells shares worth $13,503

Liquidia Corp (NASDAQ:LQDA) Chief Financial Officer and Chief Operating Officer Michael Kaseta recently executed transactions involving the company’s common stock, according to a filing with the Securities and Exchange Commission. On March 3, Kaseta sold 874 shares of Liquidia Corp at a price of $15.45 per share, totaling $13,503. The transaction comes as the stock trades near its 52-week high of $16.99, having gained over 66% in the past six months. According to InvestingPro analysis, the company’s current market capitalization stands at $1.28 billion.

Prior to this, on February 28, Kaseta acquired 2,344 shares through the conversion of Restricted Stock Units (RSUs) into common stock. The RSUs were part of a grant initially awarded on January 16, 2022, with vesting scheduled over a period extending to February 28, 2025.

Following these transactions, Kaseta holds 404,598 shares of Liquidia Corp common stock. The sale of shares on March 3 was executed under a pre-arranged trading plan adopted on December 15, 2023, to cover taxes associated with the settlement of RSUs.

In other recent news, Liquidia Corporation encountered a legal challenge when the U.S. District Court for the District of Columbia ruled against its lawsuit concerning the FDA’s decision to grant regulatory exclusivity to Tyvaso DPI, a product of United Therapeutics (NASDAQ:UTHR) Corporation. The court’s decision denied Liquidia’s motion for summary judgment while granting those filed by the FDA and United Therapeutics, thus upholding the exclusivity for Tyvaso DPI until May 23, 2025. Additionally, United Therapeutics has filed a cross claim questioning the FDA’s acceptance of Liquidia’s amended New Drug Application for review. Liquidia and the FDA have moved to dismiss this cross claim, but the court has not yet ruled on these motions. This legal development affects Liquidia’s competitive stance in the market, as it aimed to challenge the exclusivity granted to Tyvaso DPI. The information is drawn from official statements and legal documents, ensuring an accurate representation of the situation without speculative commentary.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.